SEC Comment Letter 0000000000-24-014226 to ZyVersa Therapeutics, Inc. (ZVSA)
ZyVersa Therapeutics, Inc.
Date: Dec. 23, 2024 · CIK: 0001859007 · Accession: 0000000000-24-014226
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-283993
Letter
December 23, 2024 Stephen C. Glover Chief Executive Officer ZyVersa Therapeutics, Inc. 2200 N. Commerce Parkway, Suite 208 Weston, FL 33326 Re:ZyVersa Therapeutics, Inc. Registration Statement on Form S-3 Filed December 20, 2024 File No. 333-283993 Dear Stephen C. Glover: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Joshua Gorsky at 202-551-7836 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Faith L. Charles
Show Raw Text
December 23, 2024
Stephen C. Glover
Chief Executive Officer
ZyVersa Therapeutics, Inc.
2200 N. Commerce Parkway, Suite 208
Weston, FL 33326
Re:ZyVersa Therapeutics, Inc.
Registration Statement on Form S-3
Filed December 20, 2024
File No. 333-283993
Dear Stephen C. Glover:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Joshua Gorsky at 202-551-7836 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Faith L. Charles